215 related articles for article (PubMed ID: 25025467)
1. The detection of the methylated Wif-1 gene is more accurate than a fecal occult blood test for colorectal cancer screening.
Amiot A; Mansour H; Baumgaertner I; Delchier JC; Tournigand C; Furet JP; Carrau JP; Canoui-Poitrine F; Sobhani I;
PLoS One; 2014; 9(7):e99233. PubMed ID: 25025467
[TBL] [Abstract][Full Text] [Related]
2. Detection of promoter hypermethylation of Wnt antagonist genes in fecal samples for diagnosis of early colorectal cancer.
Zhang H; Zhu YQ; Wu YQ; Zhang P; Qi J
World J Gastroenterol; 2014 May; 20(20):6329-35. PubMed ID: 24876755
[TBL] [Abstract][Full Text] [Related]
3. Fecal occult blood test for colorectal cancer screening: an evidence-based analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2009; 9(10):1-40. PubMed ID: 23074514
[TBL] [Abstract][Full Text] [Related]
4. Aberrant methylation of NPY, PENK, and WIF1 as a promising marker for blood-based diagnosis of colorectal cancer.
Roperch JP; Incitti R; Forbin S; Bard F; Mansour H; Mesli F; Baumgaertner I; Brunetti F; Sobhani I
BMC Cancer; 2013 Dec; 13():566. PubMed ID: 24289328
[TBL] [Abstract][Full Text] [Related]
5. [Chemical or immunological tests for the detection of fecal occult blood in colorectal cancer screening?].
Quintero E
Gastroenterol Hepatol; 2009 Oct; 32(8):565-76. PubMed ID: 19577340
[TBL] [Abstract][Full Text] [Related]
6. Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population.
van Rossum LG; van Rijn AF; Laheij RJ; van Oijen MG; Fockens P; van Krieken HH; Verbeek AL; Jansen JB; Dekker E
Gastroenterology; 2008 Jul; 135(1):82-90. PubMed ID: 18482589
[TBL] [Abstract][Full Text] [Related]
7. A quantitative immunochemical fecal occult blood test for colorectal neoplasia.
Levi Z; Rozen P; Hazazi R; Vilkin A; Waked A; Maoz E; Birkenfeld S; Leshno M; Niv Y
Ann Intern Med; 2007 Feb; 146(4):244-55. PubMed ID: 17310048
[TBL] [Abstract][Full Text] [Related]
8. Colorectal cancer screening: comparison of transferrin and immuno fecal occult blood test.
Chen JG; Cai J; Wu HL; Xu H; Zhang YX; Chen C; Wang Q; Xu J; Yuan XL
World J Gastroenterol; 2012 Jun; 18(21):2682-8. PubMed ID: 22690078
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the performance of guaiac-based and two immunochemical fecal occult blood tests for identifying advanced colorectal neoplasia in Taiwan.
Ou CH; Kuo FC; Hsu WH; Lu CY; Yu FJ; Kuo CH; Wang JY; Wu MT; Shiea J; Wu DC; Hu HM
J Dig Dis; 2013 Sep; 14(9):474-83. PubMed ID: 23701988
[TBL] [Abstract][Full Text] [Related]
10. Early Detection of Colorectal Cancer: a Multi-Center Pre-Clinical Case Cohort Study for Validation of a Combined DNA Stool Test.
Dollinger MM; Behl S; Fleig WE
Clin Lab; 2018 Oct; 64(10):1719-1730. PubMed ID: 30336540
[TBL] [Abstract][Full Text] [Related]
11. Immunochemical testing of individuals positive for guaiac faecal occult blood test in a screening programme for colorectal cancer: an observational study.
Fraser CG; Matthew CM; Mowat NA; Wilson JA; Carey FA; Steele RJ
Lancet Oncol; 2006 Feb; 7(2):127-31. PubMed ID: 16455476
[TBL] [Abstract][Full Text] [Related]
12. Quantitative colonoscopic evaluation of relative efficiencies of an immunochemical faecal occult blood test and a sensitive guaiac test for detecting significant colorectal neoplasms.
Rozen P; Levi Z; Hazazi R; Waked A; Vilkin A; Maoz E; Birkenfeld S; Niv Y
Aliment Pharmacol Ther; 2009 Feb; 29(4):450-7. PubMed ID: 19035980
[TBL] [Abstract][Full Text] [Related]
13. Screening for familial colorectal cancer with a sensitive immunochemical fecal occult blood test: a pilot study.
Gimeno-García AZ; Quintero E; Nicolás-Pérez D; Hernández-Guerra M; Parra-Blanco A; Jiménez-Sosa A
Eur J Gastroenterol Hepatol; 2009 Sep; 21(9):1062-7. PubMed ID: 19307978
[TBL] [Abstract][Full Text] [Related]
14. Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics.
Allison JE; Sakoda LC; Levin TR; Tucker JP; Tekawa IS; Cuff T; Pauly MP; Shlager L; Palitz AM; Zhao WK; Schwartz JS; Ransohoff DF; Selby JV
J Natl Cancer Inst; 2007 Oct; 99(19):1462-70. PubMed ID: 17895475
[TBL] [Abstract][Full Text] [Related]
15. Lower risk of advanced neoplasia among patients with a previous negative result from a fecal test for colorectal cancer.
Denters MJ; Deutekom M; Bossuyt PM; Stroobants AK; Fockens P; Dekker E
Gastroenterology; 2012 Mar; 142(3):497-504. PubMed ID: 22108194
[TBL] [Abstract][Full Text] [Related]
16. Stool DNA test targeting methylated syndecan-2 (SDC2) as a noninvasive screening method for colorectal cancer.
Su WC; Kao WY; Chang TK; Tsai HL; Huang CW; Chen YC; Li CC; Hsieh YC; Yeh HJ; Chang CC; Wang JY
Biosci Rep; 2021 Jan; 41(1):. PubMed ID: 33393623
[TBL] [Abstract][Full Text] [Related]
17. Results of National Colorectal Cancer Screening Program in Croatia (2007-2011).
Katičić M; Antoljak N; Kujundžić M; Stamenić V; Skoko Poljak D; Kramarić D; Stimac D; Strnad Pešikan M; Samija M; Ebling Z
World J Gastroenterol; 2012 Aug; 18(32):4300-7. PubMed ID: 22969192
[TBL] [Abstract][Full Text] [Related]
18. Comparative evaluation of immunochemical fecal occult blood tests for colorectal adenoma detection.
Hundt S; Haug U; Brenner H
Ann Intern Med; 2009 Feb; 150(3):162-9. PubMed ID: 19189905
[TBL] [Abstract][Full Text] [Related]
19. Colorectal Cancer Screening With Traditional and New-generation Fecal Immunochemical Tests: A Critical Review of Fecal Occult Blood Tests.
Meklin J; Syrjänen K; Eskelinen M
Anticancer Res; 2020 Feb; 40(2):575-581. PubMed ID: 32014898
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]